Barbara Weber is President and Chief Executive Officer of Tango Therapeutics, a biotechnology company she began building shortly after joining Third Rock Ventures in March 2015. Barbara has led the company from its inception to a Series A funded start-up and now a publicly traded clinical-stage company with more than 100 employees.
Prior to joining Third Rock Ventures, Barbara was Senior Vice President and Global Head, Oncology Translational Medicine at Novartis from 2009 to 2015 and Vice President, Oncology Discovery and Translational Medicine at GlaxoSmithKline from 2005 to 2009. Prior to joining the pharmaceutical industry, Barbara was Professor of Medicine and Genetics at the University of Pennsylvania, leading a clinical and translational research program in cancer genetics.
Barbara is an elected member of the American Association of Physicians and the American Society for Clinical Investigation, of which she served as President in 2005. Barbara also has served on the board of directors of both ASCO and AACR. Barbara serves on the board of directors of Revolution Medicines, FogPharma, and OPY Acquisition Corp I.
After earning her Bachelor of Science degree in chemistry from the University of Washington, Barbara graduated from the University of Washington School of Medicine. She completed her residency in internal medicine at Yale University and a fellowship in medical oncology at the Dana-Farber Cancer Institute.
What is Barbara Weber's net worth?
The estimated net worth of Barbara Weber is at least $16.15 million as of February 4th, 2025. Weber owns 1,631,264 shares of Tango Therapeutics stock worth more than $16,149,514 as of December 5th. This net worth estimate does not reflect any other investments that Weber may own. Additionally, Weber receives a salary of $1,040,000.00 as CEO at Tango Therapeutics. Learn More about Barbara Weber's net worth.
How old is Barbara Weber?
What is Barbara Weber's salary?
How do I contact Barbara Weber?
Has Barbara Weber been buying or selling shares of Tango Therapeutics?
Barbara Weber has not been actively trading shares of Tango Therapeutics within the last three months. Most recently, Barbara Weber sold 9,778 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a transaction totalling $29,236.22. Following the completion of the sale, the chief executive officer now directly owns 1,631,264 shares of the company's stock, valued at $4,877,479.36. Learn More on Barbara Weber's trading history.
Who are Tango Therapeutics' active insiders?
Are insiders buying or selling shares of Tango Therapeutics?
During the last year, insiders at the sold shares 11 times. They sold a total of 3,496,769 shares worth more than $26,422,881.47. The most recent insider tranaction occured on October, 23rd when Major Shareholder Rock Ventures Iv L.P. Third sold 477,401 shares worth more than $4,845,620.15. Insiders at Tango Therapeutics own 7.5% of the company.
Learn More about insider trades at Tango Therapeutics. Information on this page was last updated on 10/23/2025.
